ELI LILLY AND CO. news, videos and press releases - Page 6
For more news please use our advanced search feature.
ELI LILLY AND CO. - More news...
ELI LILLY AND CO. - More news...
- AAN 2018: Lilly's Galcanezumab Significantly Reduced Monthly Migraine Headache Days in Patients with Migraine Who Previously Failed to Respond to Multiple Preventive Therapies
- FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis
- Lilly Reports Additional Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 RANGE Study in Advanced or Metastatic Urothelial Cancer
- Lilly to Present Phase 3 Data at AAN 2018 Reinforcing Commitment to New, Innovative Therapies in Migraine
- Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford to investigate the effects of Jardiance® in adults with chronic kidney disease
- Lilly Confirms Date and Conference Call for First-Quarter 2018 Financial Results Announcement
- Lilly and Sigilon Therapeutics Announce Strategic Collaboration to Develop Encapsulated Cell Therapies for the Treatment of Type 1 Diabetes
- Lilly Announces CYRAMZA® (ramucirumab) Phase 3 REACH-2 Study in Second-Line Hepatocellular Carcinoma Patients Met Overall Survival Endpoint
- Maura Dickler, M.D., to become Vice President of Late Phase Development at Lilly Oncology
- EFSD, JDRF and Lilly Extend Collaboration Supporting Type 1 Diabetes Research
- Boehringer Ingelheim and Lilly expand heart failure program for Jardiance® with new exercise capacity trials
- Lilly Receives Additional FDA Approval for VerzenioTM (abemaciclib), as Initial Treatment for Advanced Breast Cancer
- New Data Show Lilly's Trulicity® (dulaglutide) in Combination with an SGLT-2 Inhibitor Improves Blood Sugar Control in People with Type 2 Diabetes
- Lilly to Participate in Barclays Global Healthcare Conference
- New Research: Key Drivers of Growth for SpartanNash, Nustar GP, Hornbeck Offshore Services, TiVo, Eli Lilly, and Rigel Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production
- Lilly to Participate in Cowen Health Care Conference
- Survey Reveals Many People with Migraine Live with Pain Nearly Half of Every Month
- AAD 2018: Treatment with Lilly's Taltz® (ixekizumab) Resulted in Improvement in Impact of Genital Psoriasis on Sexual Activity
- Lilly to Showcase New Data for Taltz® (ixekizumab) and Other Products Across Immunology Pipeline at AAD Annual Meeting
- Lilly Announces Positive Top-Line Phase 3 Results for Taltz® (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
- Lilly Reports Strong Fourth-Quarter and Full-Year 2017 Revenue Growth, Increases 2018 EPS Guidance
- Lilly To Present At Leerink Partners Global Healthcare Conference
- Livongo and Lilly Collaborate on Real-World Diabetes Research
- Lilly Confirms Date and Conference Call for Fourth-Quarter 2017 Financial Results Announcement
- Lilly to Present at J.P. Morgan Healthcare Conference
- Lilly to Participate in Goldman Sachs Healthcare CEOs Unscripted Conference
- Rimidi and Lilly Collaborate to Personalize Solutions for People Using Insulin
- Lilly Announces 2018 Financial Guidance and Enhances Outlook Through 2020
- Lilly Announces 8 Percent Dividend Increase
- FDA Accepts Biologics License Application (BLA) to Review Galcanezumab for the Prevention of Migraine in Adults
